Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Mark Sabag Sells 46,000 Shares

Key Points

• Insider Mark Sabag sold 46,000 Teva shares for about $1.93 million, reducing his direct stake by 36.29% to 80,760 shares.
• Teva reported quarterly EPS of $0.86, beating the $0.72 consensus, and revenue of $4.39 billion, above estimates; revenue nevertheless fell 1.9% year over year.
• Shares traded at $42.52, near their 12-month high of $43.34. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $47.23.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Mark Sabag sold 46,000 shares of the business's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the sale, the insider directly owned 80,760 shares of the company's stock, valued at approximately $3,386,266.80. This represents a 36.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.74 on Friday, hitting $42.52. 6,131,455 shares of the company's stock were exchanged, compared to its average volume of 6,848,926. The company has a current ratio of 0.95, a quick ratio of 0.67 and a debt-to-equity ratio of 1.59. The stock has a fifty day moving average of $39.39 and a two-hundred day moving average of $34.73. Teva Pharmaceutical Industries Ltd. has a twelve month low of $23.61 and a twelve month high of $43.34. The firm has a market cap of $49.55 billion, a PE ratio of 98.88, a P/E/G ratio of 3.92 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. Teva Pharmaceutical Industries's quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva said sales of its three key branded medicines grew 33% last quarter. The company also improved margins and reduced net debt, supporting its turnaround and financial position. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and it raised its 2026 revenue and product-sales outlook, citing strength in branded drugs. The improved outlook may help offset the revenue decline. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: Analyst commentary is bullish: Leerink Partners raised its price target to $52 from $45 and maintained an outperform rating; HC Wainwright also reiterated a Buy rating and $52 target. TD Cowen was reported to see potential for further appreciation. Article: Leerink Partners Raises Teva Price Target Article: TD Cowen Forecasts Strong Price Appreciation
• Negative Sentiment: Quarterly revenue slipped, a sign that growth remains uneven despite the stronger branded-drug performance and raised outlook. Article: Teva Stock: Q3 Revenue Slips as 2026 Outlook Rises

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently added to or reduced their stakes in the business. WCM Investment Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. SEB Asset Management AB purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at $59,551,000. Assenagon Asset Management S.A. lifted its holdings in shares of Teva Pharmaceutical Industries by 128.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company's stock valued at $103,538,000 after purchasing an additional 1,716,315 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares during the last quarter. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $33,799,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TEVA shares. Leerink Partners raised their target price on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday. Oppenheimer upped their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a research report on Friday, October 9th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an "overweight" rating in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Finally, HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Monday. They issued a "buy" rating and a $52.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and an average target price of $47.23.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world's largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva's portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.